Città di Lecce Hospital, GVM Care & Research, Lecce, Italy.
Cardiovascular Center, Paracelsus Medical University, Nuremberg, Germany.
Eur J Cardiothorac Surg. 2019 Jul 1;56(1):38-43. doi: 10.1093/ejcts/ezy477.
The ideal strategy for the treatment of severe aortic valve stenosis in patients of varying risk categories has become a debated topic in the last years: should the transcatheter or surgical approach be adopted? The aim of this study was to evaluate the outcomes of low-, intermediate-, high- and very high-risk patients undergoing sutureless, rapid deployment aortic valve replacement.
From 2007 to 2017, data on a total of 3651 patients were collected from the Sutureless and Rapid Deployment Aortic Valve Replacement International Registry (SURD-IR). Of these, 2057 patients who underwent primary isolated aortic valve replacement were considered for this analysis and classified as being at low (EuroSCORE <5; n = 500), intermediate (EuroSCORE 5-10; n = 901), high (EuroSCORE 11-20; n = 500) and very high (EuroSCORE >20; n = 156) preoperative risk.
Overall, a less invasive approach was used in 74.1% of patients and represented the most frequent (>50%) approach in all risk categories. The Perceval prosthesis was used more frequently than other devices, especially in patients at high and very high risk. Hospital mortality was 1.6%, 0.8%, 1.9% and 2.7% in low-, intermediate-, high- and very high-risk patients, respectively, with no significant differences among subgroups. Similarly, postoperative complication rates were similar across the different risk categories.
Surgical aortic valve replacement using sutureless, rapid deployment biological valve prostheses is associated with excellent results and represents a safe and effective treatment option for patients with severe aortic valve stenosis. This seems to be particularly true in patients with a higher risk profile.
在不同风险类别的患者中,治疗严重主动脉瓣狭窄的理想策略一直是一个备受争议的话题:应该采用经导管还是手术方法?本研究旨在评估采用无缝线、快速部署主动脉瓣置换术治疗低危、中危、高危和极高危患者的结果。
2007 年至 2017 年,共从无缝线和快速部署主动脉瓣置换国际注册处(SURD-IR)收集了 3651 例患者的数据。在这些患者中,共有 2057 例接受了原发性孤立性主动脉瓣置换术,被认为适合本分析,并分为低危(EuroSCORE<5;n=500)、中危(EuroSCORE 5-10;n=901)、高危(EuroSCORE 11-20;n=500)和极高危(EuroSCORE>20;n=156)术前风险。
总体而言,74.1%的患者采用了微创方法,并且在所有风险类别中,微创方法是最常见的(>50%)。与其他器械相比,Perceval 假体的使用更为频繁,尤其是在高危和极高危患者中。低危、中危、高危和极高危患者的住院死亡率分别为 1.6%、0.8%、1.9%和 2.7%,亚组间无显著差异。同样,术后并发症发生率在不同风险类别中相似。
采用无缝线、快速部署生物瓣假体的外科主动脉瓣置换术具有良好的效果,是严重主动脉瓣狭窄患者安全有效的治疗选择。对于风险较高的患者尤其如此。